An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

CompletedOBSERVATIONAL

Enrollment

1,132

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Pancreatic CancerNeoadjuvant

Interventions

DRUG

Neoadjuvant treatment

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

All Listed Sponsors

lead

Seoul National University Hospital

OTHER

NCT06129812 - An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter